Overview

This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.

Eligibility

Inclusion Criteria:

• Diagnosis of pancreatic ductal adenocarcinoma
• Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies
• Patients must have adequate organ function

Exclusion Criteria:

• Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation
• Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention
• Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation
• Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy
• Clinically significant cardiovascular disease
• Uncontrolled hypertension
• Inability to swallow tablets